1.Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.
Kwang Hyun CHUNG ; Ji Kon RYU ; Jun Hyuk SON ; Jae Woo LEE ; Dong Kee JANG ; Sang Hyub LEE ; Yong Tae KIM
Gut and Liver 2017;11(2):298-305
BACKGROUND/AIMS: Second-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC) that progresses following gemcitabine-based treatment has not been established. This study aimed to investigate the efficacy and safety of second-line combination chemotherapy with capecitabine and oxaliplatin (XELOX) in these patients. METHODS: Between August 2011 and May 2014, all patients who received at least one cycle of XELOX (capecitabine, 1,000 mg/m² twice daily for 14 days; oxaliplatin, 130 mg/m² on day 1 of a 3-week cycle) combination chemotherapy for unresectable or recurrent PDAC were retrospectively recruited. The response was evaluated every 9 weeks, and the tumor response rate, progression-free survival and overall survival, and adverse events were assessed. RESULTS: Sixty-two patients were included; seven patients (11.3%) had a partial tumor response, and 20 patients (32.3%) had stable disease. The median progression-free and overall survival were 88 days (range, 35.1 to 140.9 days) and 158 days (range, 118.1 to 197.9 days), respectively. Patients who remained stable longer with frontline therapy (≥120 days) exhibited significantly longer progression-free and overall survival. The most common grade 3 to 4 adverse events in patients were vomiting (8.1%) and anorexia (6.5%). There was one treatment-related mortality caused by severe neutropenia and typhlitis. CONCLUSIONS: Second-line XELOX combination chemotherapy demonstrated an acceptable response and survival rate in patients with advanced PDAC who had failed gemcitabine-based chemotherapy.
Adenocarcinoma
;
Anorexia
;
Capecitabine*
;
Carcinoma, Pancreatic Ductal
;
Disease-Free Survival
;
Drug Therapy
;
Drug Therapy, Combination*
;
Humans
;
Mortality
;
Neutropenia
;
Pancreatic Ducts
;
Pancreatic Neoplasms*
;
Retrospective Studies
;
Salvage Therapy
;
Survival Rate
;
Treatment Outcome
;
Typhlitis
;
Vomiting
2.Preoperative biliary drainage for pancreatic cancer
Gastrointestinal Intervention 2018;7(2):67-73
Pancreatic cancer is a leading cause of cancer-related morbidity and mortality, but any meaningful improvement in its prognosis remains elusive. The lack of early diagnostic methods means that many patients only present when symptoms develop, such as obstructive jaundice. Once a diagnosis of pancreatic cancer has been made in a patient with obstructive jaundice, then a decision should be made if the patient is a candidate for surgical resection. Patients who are candidates for surgical resection generally do not need preoperative biliary drainage, unless they present with cholangitis, or if they require neo-adjuvant chemotherapy. If preoperative biliary drainage is to be done, then patient factors and local expertise should guide appropriate interventions. The evidence for endoscopic retrograde cholangiopancreatography as a first-line therapy for biliary decompression is strong; However, the use of percutaneous transhepatic biliary drainage as well as endoscopic ultrasound-guided biliary drainage has generally not been found to be inferior. Finally, to ensure ongoing patency and minimize complications, an appropriate self-expanding metal stent should ideally be placed.
Cholangiopancreatography, Endoscopic Retrograde
;
Cholangitis
;
Decompression
;
Diagnosis
;
Drainage
;
Drug Therapy
;
Endoscopy
;
Humans
;
Jaundice, Obstructive
;
Mortality
;
Pancreatic Neoplasms
;
Prognosis
;
Stents
;
Ultrasonography
3.Relief of Obstruction in the Management of Pancreatic Cancer
The Korean Journal of Gastroenterology 2019;74(2):69-80
Pancreatic cancer is a major cause of cancer-related mortality and morbidity, and its incidence is increasing as the population is aging. On the other hand, significant improvement in the prognosis has not occurred. The absence of early diagnosis means that many patients are diagnosed only when they develop symptoms, such as jaundice, due to a biliary obstruction. The role of endoscopy in multidisciplinary care for patients with pancreatic cancer continues to evolve. Controversy remains regarding the best preoperative biliary drainage in patients with surgically resectable pancreatic head cancer. In general, patients undergoing a surgical resection usually do not require preoperative biliary drainage unless they have cholangitis or receive neoadjuvant chemotherapy. If biliary drainage is performed prior to surgery, the patient's condition and a multidisciplinary approach should be considered. With the increasing life expectancy of patients with pancreatic cancer, the need for more long-time biliary drainage or pre-operative biliary drainage is also increasing. Strong evidence of endoscopic retrograde cholangiopancreatography (ERCP) as a first-line and essential treatment for biliary decompression has been provided. On the other hand, the use of endoscopic ultrasound-guided biliary drainage as well as percutaneous biliary drainage has been also recommended. During ERCP, self-expandable metal stent could be recommended instead of a plastic stent for the purpose of long stent patency and minimizing stent-induced complications. In this review, several points of view regarding the relief of obstruction in patients with pancreatic cancer, and optimal techniques are being discussed.
Aging
;
Cholangiopancreatography, Endoscopic Retrograde
;
Cholangitis
;
Decompression
;
Drainage
;
Drug Therapy
;
Early Diagnosis
;
Endoscopy
;
Hand
;
Head and Neck Neoplasms
;
Humans
;
Incidence
;
Jaundice
;
Life Expectancy
;
Mortality
;
Pancreatic Neoplasms
;
Plastics
;
Prognosis
;
Stents
4.Relief of Obstruction in the Management of Pancreatic Cancer
The Korean Journal of Gastroenterology 2019;74(2):69-80
Pancreatic cancer is a major cause of cancer-related mortality and morbidity, and its incidence is increasing as the population is aging. On the other hand, significant improvement in the prognosis has not occurred. The absence of early diagnosis means that many patients are diagnosed only when they develop symptoms, such as jaundice, due to a biliary obstruction. The role of endoscopy in multidisciplinary care for patients with pancreatic cancer continues to evolve. Controversy remains regarding the best preoperative biliary drainage in patients with surgically resectable pancreatic head cancer. In general, patients undergoing a surgical resection usually do not require preoperative biliary drainage unless they have cholangitis or receive neoadjuvant chemotherapy. If biliary drainage is performed prior to surgery, the patient's condition and a multidisciplinary approach should be considered. With the increasing life expectancy of patients with pancreatic cancer, the need for more long-time biliary drainage or pre-operative biliary drainage is also increasing. Strong evidence of endoscopic retrograde cholangiopancreatography (ERCP) as a first-line and essential treatment for biliary decompression has been provided. On the other hand, the use of endoscopic ultrasound-guided biliary drainage as well as percutaneous biliary drainage has been also recommended. During ERCP, self-expandable metal stent could be recommended instead of a plastic stent for the purpose of long stent patency and minimizing stent-induced complications. In this review, several points of view regarding the relief of obstruction in patients with pancreatic cancer, and optimal techniques are being discussed.
Aging
;
Cholangiopancreatography, Endoscopic Retrograde
;
Cholangitis
;
Decompression
;
Drainage
;
Drug Therapy
;
Early Diagnosis
;
Endoscopy
;
Hand
;
Head and Neck Neoplasms
;
Humans
;
Incidence
;
Jaundice
;
Life Expectancy
;
Mortality
;
Pancreatic Neoplasms
;
Plastics
;
Prognosis
;
Stents
5.Octreotide acetate long-acting release in treatment of pancreatic neuroendocrine tumors.
Shi ZHANG ; Yu-xiu LI ; Nai-shi LI ; Wen-hui LI ; Hui-juan ZHU ; Feng GU ; Heng WANG
Chinese Medical Journal 2009;122(13):1582-1584
6.Percutaneous Radiofrequency Ablation for Metachronous Hepatic Metastases after Curative Resection of Pancreatic Adenocarcinoma
So Jung LEE ; Jin Hyoung KIM ; So Yeon KIM ; Hyung Jin WON ; Yong Moon SHIN ; Pyo Nyun KIM
Korean Journal of Radiology 2020;21(3):316-324
OBJECTIVE: To retrospectively evaluate the safety and efficacy of percutaneous radiofrequency ablation (RFA) in patients with metachronous hepatic metastases arising from pancreatic adenocarcinoma who had previously received curative surgery.MATERIALS AND METHODS: Between 2002 and 2017, percutaneous RFA was performed on 94 metachronous hepatic metastases (median diameter, 1.5 cm) arising from pancreatic cancer in 60 patients (mean age, 60.5 years). Patients were included if they had fewer than five metastases, a maximum tumor diameter of ≤ 5 cm, and disease confined to the liver or stable extrahepatic disease. For comparisons during the same period, we included 66 patients who received chemotherapy only and met the same eligibility criteria described.RESULTS: Technical success was achieved in all hepatic metastasis without any procedure-related mortality. During follow-up, local tumor progression of treated lesions was observed in 38.3% of the tumors. Overall median survival and 3-year survival rates were 12 months and 0%, respectively from initial RFA, and 14.7 months and 2.1%, respectively from the first diagnosis of liver metastasis. Multivariate analysis showed that a large tumor diameter of > 1.5 cm, a late TNM stage (≥ IIB) before curative surgery, a time from surgery to recurrence of < 1 year, and the presence of extrahepatic metastasis, were all prognostic of reduced overall survival after RFA. Median overall (12 months vs. 9.1 months, p = 0.094) and progression-free survival (5 months vs. 3.3 months, p = 0.068) were higher in the RFA group than in the chemotherapy group with borderline statistical difference.CONCLUSION: RFA is safe and may offer successful local tumor control in patients with metachronous hepatic metastases arising from pancreatic adenocarcinoma. Patients with a small diameter tumor, early TNM stage before curative surgery, late hepatic recurrence, and liver-only metastasis benefit most from RFA treatment. RFA provided better survival outcomes than chemotherapy for this specific group with borderline statistical difference.
Adenocarcinoma
;
Catheter Ablation
;
Diagnosis
;
Disease-Free Survival
;
Drug Therapy
;
Follow-Up Studies
;
Humans
;
Liver
;
Mortality
;
Multivariate Analysis
;
Neoplasm Metastasis
;
Pancreatic Neoplasms
;
Recurrence
;
Retrospective Studies
;
Survival Rate
7.Salvage Chemotherapy after Gemcitabine Failure in Patients with Advanced Pancreatic Cancer: Survival Benefit in Selected Patients.
The Korean Journal of Gastroenterology 2008;52(1):59-63
No abstract available.
Angiogenesis Inhibitors/therapeutic use
;
Antibodies, Monoclonal/therapeutic use
;
Antimetabolites, Antineoplastic/*therapeutic use
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
;
Deoxycytidine/*analogs & derivatives/therapeutic use
;
Drug Resistance, Neoplasm
;
Humans
;
Pancreatic Neoplasms/*drug therapy/mortality/pathology
;
*Salvage Therapy
;
Survival Analysis
;
Treatment Failure
8.En bloc Resection for Right Colon Cancer Directly Invading Duodenum or Pancreatic Head.
Won Suk LEE ; Woo Yong LEE ; Ho Kyung CHUN ; Seong Ho CHOI
Yonsei Medical Journal 2009;50(6):803-806
PURPOSE: We undertook this study to analyze clinical features and surgical outcome of en bloc resections of the right side colon cancer directly invading duodenum and/or pancreatic head. MATERIALS AND METHODS: The records of all patients who underwent en bloc resection of duodenum and/or pancreas for right colon cancers were analyzed retrospectively. From September 1994 to September 2006, 1,016 patients underwent curative right hemicolectomy. Nine patients (0.9%) had en bloc resection of a right side colon cancer with duodenum or pancreatic head invasion. RESULTS: The median operative time was 320 minutes (range, 200-420) and the median blood loss was 700 mL (range, 100-2,000). The mean size of tumor was 6.6 cm (range, 3.2-10.7). The mean preoperative carcinoembryonic antigen (CEA) was 10.6 ng/mL (range, 0.2-50.8). There was no 30 day perioperative mortality. The median disease-free survival was 23.5 months [95% confidence interval (CI) 5.2-41.8] and the median overall survival was 28.1 months (95% CI 9.7-46.5). CONCLUSIONS: In patients with locally advanced right side colon cancer that directly invades the duodenum or pancreas can be safely resected with curative potential with minimum morbidity and mortality. Long term disease free survival can occur in a significant number of patients undergoing curative en bloc resection in this particular subset of patients.
Adult
;
Aged
;
Camptothecin/analogs & derivatives/pharmacology/therapeutic use
;
Chemotherapy, Adjuvant
;
Colonic Neoplasms/*complications/drug therapy/mortality/*surgery
;
Disease-Free Survival
;
Duodenal Neoplasms/drug therapy/mortality/*secondary/surgery
;
Duodenum/drug effects/*pathology/surgery
;
Female
;
Fluorouracil/pharmacology/therapeutic use
;
Humans
;
Leucovorin/pharmacology/therapeutic use
;
Male
;
Middle Aged
;
Organoplatinum Compounds/pharmacology/therapeutic use
;
Pancreas/drug effects/*pathology/surgery
;
Pancreatic Neoplasms/drug therapy/mortality/*secondary/surgery
;
Retrospective Studies
;
Treatment Outcome
9.Massive Pulmonary Embolism with Thrombus-in-Transit Entrapped by a Patent Foramen Ovale
Ju Yeon OH ; Woo Jin LEE ; Hak Jin KIM
Korean Journal of Medicine 2018;93(1):61-64
“Thrombus-in-transit” in pulmonary embolism is associated with high mortality and refers to a free-floating clot in the right atrium or right ventricle, indicating that deep vein thrombosis is present en route to the pulmonary artery. Thrombus entrapped in a patent foramen ovale (PFO) is a rare condition and is associated with paradoxical systemic embolism. Here, we report a case of acute pulmonary embolism with thrombus-in-transit through a PFO in a 68-year-old woman with a diagnosis of metastatic pancreatic cancer undergoing palliative chemotherapy. She presented with syncope after acute onset of exertional dyspnea and was diagnosed with cardiogenic shock due to massive pulmonary embolism with thrombus-in-transit on admission to the emergency room. We treated her with systemic thrombolysis and anticoagulation therapy instead of surgical thrombectomy. We show that hemodynamically unstable pulmonary embolism with thrombus-in-transit entrapped by a PFO may be successfully treated with systemic thrombolysis without paradoxical embolism.
Aged
;
Diagnosis
;
Drug Therapy
;
Dyspnea
;
Embolism
;
Embolism, Paradoxical
;
Emergency Service, Hospital
;
Female
;
Foramen Ovale
;
Foramen Ovale, Patent
;
Heart Atria
;
Heart Ventricles
;
Humans
;
Mortality
;
Pancreatic Neoplasms
;
Pulmonary Artery
;
Pulmonary Embolism
;
Shock, Cardiogenic
;
Syncope
;
Thrombectomy
;
Thrombolytic Therapy
;
Thrombosis
;
Venous Thrombosis
10.Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.
Chen JIN ; Lie YAO ; Jiang LONG ; De-liang FU ; Xian-jun YU ; Jin XU ; Feng YANG ; Quan-xing NI
Chinese Medical Journal 2009;122(3):284-290
BACKGROUNDRegional intra-arterial infusion chemotherapy (RIAC) has been more valuable to improve prognosis and quality of life of patients with inoperable pancreatic adenocarcinomas, and adjuvant RIAC plays an important role in prolonging survival and reducing risk of liver metastasis after radical resection of pancreatic cancer, but the effect of preoperative or multiple-phase RIAC (preoperative combined with postoperative RIAC) for resectable pancreatic cancers has not been investigated. In this prospective study, the effect of multiple-phase RIAC for patients with resectable pancreatic head adenocarcinoma was evaluated, and its safety and validity comparing with postoperative RIAC were also assessed.
METHODSPatients with resectable pancreatic head cancer were randomly assigned to two groups. Patients in group A (n=50) were treated with new therapeutic mode of extended pancreaticoduodenectomy combined with multiple-phase RIAC, and those in group B (n=50) were treated with extended pancreaticoduodenectomy combined with postoperative RIAC in the same period. The feasibility, compliance and efficiency of the new therapeutic mode were evaluated by tumor size, serum tumor markers, clinical benefit response (CBR), surgical complications, mortality and toxicity of RIAC. The disease-free survival time, median survival time, incidence of liver metastasis, survival rate at 1, 2, 3 and 5 years were also observed. Life curves were generated by the Kaplan-Meier method.
RESULTSThe pain relief rate and CBR in group A was 80% and 84% respectively. Serum tumor markers decreased obviously and tumors size decreased in 26% of patients after preoperative RIAC in group A. No more surgical complications, mortality or severe systemic side effects were observed in group A compared with group B. The incidence of liver metastasis in group A was 34% which was lower than 50% in group B. The disease-free survival time and median survival time in group A were 15.5 months and 18 months respectively. The 1-, 2-, 3- and 5-year survival rates were 54.87%, 34.94%, 24.51% and 12.25% respectively. There was no significant difference of survival time or survival rates between two groups.
CONCLUSIONSMultiple-phase RIAC is effective in combined therapy of resectable pancreatic head carcinomas by enhancing inhibition of tumor growth and reduction of liver metastasis, without negative effect on patients' safety or surgical procedure.
Adenocarcinoma ; drug therapy ; mortality ; pathology ; surgery ; Adult ; Aged ; Deoxycytidine ; analogs & derivatives ; therapeutic use ; Disease-Free Survival ; Female ; Fluorouracil ; therapeutic use ; Humans ; Infusions, Intra-Arterial ; methods ; Liver Neoplasms ; secondary ; Male ; Middle Aged ; Mitomycin ; therapeutic use ; Neoplasm Metastasis ; Pancreas ; drug effects ; pathology ; surgery ; Pancreatic Neoplasms ; drug therapy ; mortality ; pathology ; surgery ; Pancreaticoduodenectomy